share_log

Benchmark Maintains Speculative Buy on Biolase, Lowers Price Target to $0.4

Moomoo 24/7 ·  Mar 22 13:42

Benchmark analyst Bruce Jackson maintains Biolase (NASDAQ:BIOL) with a Speculative Buy and lowers the price target from $2.5 to $0.4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment